Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment
July 03, 2024 09:00 ET
|
Autonomix Medical, Inc.
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company’s ongoing human clinical trial THE...
Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
June 18, 2024 08:00 ET
|
Autonomix Medical, Inc.
The first five patients successfully completed protocols with no immediate procedural-related complications or significant adverse events; Pain relief for responder group was experienced as quick as 1...
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer
June 17, 2024 16:05 ET
|
Autonomix Medical, Inc.
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX)...
Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024
June 10, 2024 08:00 ET
|
Autonomix Medical, Inc.
Management to host live webcast to discuss results on Tuesday, June 18th at 8:30 a.m. ET THE WOODLANDS, TX, June 10, 2024 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX)...
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
June 03, 2024 08:15 ET
|
Autonomix Medical, Inc.
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
May 31, 2024 08:05 ET
|
Autonomix Medical, Inc.
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate...
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
May 23, 2024 09:15 ET
|
Autonomix Medical, Inc.
Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass Lori Bisson, Chief Executive Officer...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
May 14, 2024 16:15 ET
|
Autonomix Medical, Inc.
Live webcast on Thursday, May 16th at 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company...
Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip
April 25, 2024 08:30 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, April 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
April 24, 2024 09:00 ET
|
Autonomix Medical, Inc.
Live webcast on Wednesday, May 1st at 3:20 PM ET THE WOODLANDS, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device...